Trial Profile
An Exploratory, Randomised, Open-Label, Two-Period, Crossover Study in Healthy Subjects to Evaluate the Effect of SMP-028 on the Pharmacokinetics of Midazolam.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Aug 2016
Price :
$35
*
At a glance
- Drugs SMP 028 (Primary) ; Midazolam
- Indications Allergic rhinitis; Asthma; Seizures
- Focus Pharmacokinetics
- Sponsors Dainippon Sumitomo Pharma
- 31 Jul 2010 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
- 31 Jul 2010 Actual end date (31 Jul 2010) added as reported by ISRCTN: Current Controlled Trials.
- 19 Apr 2010 New trial record